Clinical Trials on Refractory Malignant Glioma

Total 9262 results

City of Hope Medical Center
National Cancer Institute (NCI); Food and Drug Administration (FDA)

Active, not recruiting

Genetically Modified T-cells in Treating Patients With Recurrent or Refractory Malignant Glioma

Recurrent Glioblastoma | Recurrent Malignant Glioma | Refractory Malignant Glioma | Recurrent WHO Grade III Glioma | Recurrent WHO Grade II Glioma | Refractory Glioblastoma | Refractory WHO Grade II Glioma | Refractory WHO Grade III Glioma

United States
National Cancer Institute (NCI)

Recruiting

Volitinib in Treating Patients With Recurrent or Refractory Primary CNS Tumors

Recurrent Malignant Glioma | Recurrent Medulloblastoma | Refractory Malignant Glioma | Refractory Medulloblastoma | Recurrent Diffuse Intrinsic Pontine Glioma | Recurrent Primary Central Nervous System Neoplasm | Refractory Primary Central Nervous System Neoplasm | Refractory Diffuse Intrinsic Pontine...

United States, Canada
Sanofi

Completed

A Study of XL765 (SAR245409) in Combination With Temozolomide With and Without Radiation in Adults With Malignant Gliomas

Glioblastoma Multiforme | Malignant Gliomas | Mixed Gliomas

United States
Universitaire Ziekenhuizen KU Leuven

Unknown

Multimodal MR Imaging in Patients With Glioblastoma Treated With Dendritic Cell Therapy

Malignant Gliomas

Belgium
Ralph NULL Salloum
Children's Hospital Medical Center, Cincinnati

Recruiting

Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors

High Grade Glioma | Medulloblastoma | Meningioma | Anaplastic Ependymoma | Recurrent Malignant Glioma | Recurrent Medulloblastoma | Refractory Malignant Glioma | Refractory Medulloblastoma | Recurrent Diffuse Intrinsic Pontine Glioma | Recurrent Primary Central Nervous System Neoplasm | Refractory Primary... and other conditions

United States
Tata Memorial Hospital

Completed

Fluorescence and Glioma Heterogeneity (ALAglioma)

Malignant Gliomas

India
National Cancer Institute (NCI)

Terminated

Sunitinib to Treat Recurrent Brain Cancer

Glioblastoma Multiforme | Malignant Gliomas | Anaplastic Gliomas

United States
Constantinos Hadjipanayis
Massachusetts General Hospital

Completed

5-Aminolevulinic Acid (5-ALA) to Enhance Visualization of Malignant Tumor

Malignant Gliomas

United States
Dana-Farber Cancer Institute
Massachusetts General Hospital; Beth Israel Deaconess Medical Center; Brigham... and other collaborators

Completed

Study of Lenalidomide and XRT in Patients With Newly Diagnosed Glioblastoma Multiforme

Glioblastoma | Gliosarcoma | Malignant Gliomas

United States
University of Colorado, Denver
AstraZeneca

Completed

Dose Escalation Study of Vandetanib With Hypofractionated Stereotactic Radiotherapy in Recurrent Malignant Gliomas (IRUSZACT0073)

Malignant Gliomas

United States
Peking Union Medical College Hospital
Beijing Tiantan Hospital; Tianjin Medical University General Hospital

Unknown

Efficacy and Safety of TMZ Plus CDDP in the Patients With Recurrent Malignant Gliomas

Malignant Gliomas

China
National Cancer Institute (NCI)

Recruiting

Studying the Biology of IDH-mutant Gliomas Via Longitudinal Observation of 2-hydroxyglutarate (2-HG) Using MR Spectroscopy

Glioma | High Grade Glioma | Malignant Glioma | Gliomas | Low Grade Glioma

United States
National Cancer Institute (NCI)
Children's Oncology Group

Active, not recruiting

Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial)

Refractory Malignant Solid Neoplasm | Recurrent Ependymoma | Recurrent Ewing Sarcoma | Recurrent Hepatoblastoma | Recurrent Langerhans Cell Histiocytosis | Recurrent Malignant Germ Cell Tumor | Recurrent Malignant Glioma | Recurrent Malignant Solid Neoplasm | Recurrent Medulloblastoma | Recurrent Neuroblastoma and other conditions

United States, Puerto Rico, Australia
London Health Sciences Centre
University of Western Ontario, Canada; London Regional Cancer Program, Canada

Terminated

Imaging Study of Glioblastomas Treated With Avastin

Malignant Gliomas

Canada
Rigshospitalet, Denmark
Odense University Hospital; Aalborg University Hospital

Completed

Cetuximab, Bevacizumab and Irinotecan for Patients With Malignant Glioblastomas

Malignant Gliomas

Denmark
M.D. Anderson Cancer Center
Celgene

Terminated

Irinotecan Plus Lenalidomide in Adult Patients With Recurrent Glioblastoma Multiforme: Phase I

Malignant Gliomas

United States
Neurological Surgery, P.C.

Terminated

Study of LBH589 (Panobinostat) to Treat Malignant Brain Tumors

Recurrent Malignant Gliomas

United States
National Cancer Institute (NCI)

Active, not recruiting

Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)

Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Recurrent Ependymoma | Recurrent Hepatoblastoma | Recurrent Langerhans Cell Histiocytosis | Recurrent Malignant Germ Cell Tumor | Recurrent Malignant Glioma | Recurrent Malignant Solid Neoplasm | Recurrent Medulloblastoma | Recurrent... and other conditions

United States, Puerto Rico
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Memory-Enriched T Cells in Treating Patients With Recurrent or Refractory Grade III-IV Glioma

Glioblastoma | Malignant Glioma | WHO Grade III Glioma | Recurrent Glioma | Refractory Glioma

United States
National Cancer Institute (NCI)
Children's Oncology Group

Active, not recruiting

Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial

Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Recurrent Ependymoma | Recurrent Ewing Sarcoma | Recurrent Hepatoblastoma | Recurrent Histiocytic and Dendritic Cell Neoplasm | Recurrent Langerhans Cell Histiocytosis | Recurrent Lymphoma | Recurrent Malignant Germ Cell Tumor | Recurrent Malignant... and other conditions

United States, Puerto Rico, Australia
University of Texas Southwestern Medical Center
National Cancer Institute (NCI); National Institutes of Health (NIH)

Completed

Clinical Development of Cancer-Specific MRS Biomarkers in Malignant Gliomas

Malignant Gliomas | Astrocytomas | Oligodendrogliomas

United States
National Cancer Institute (NCI)

Active, not recruiting

Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)

Recurrent Childhood Ependymoma | Advanced Malignant Solid Neoplasm | Recurrent Ewing Sarcoma | Recurrent Hepatoblastoma | Recurrent Langerhans Cell Histiocytosis | Recurrent Malignant Germ Cell Tumor | Recurrent Malignant Glioma | Recurrent Medulloblastoma | Recurrent Neuroblastoma | Recurrent Non-Hodgkin... and other conditions

United States, Puerto Rico
Tocagen Inc.

Terminated

A Continuation Protocol for Patients Previously Enrolled in a Study of Toca 511

Astrocytoma | Glioblastoma Multiforme | Gliomas, Malignant

United States
University of Alberta
Capital Health, Canada

Completed

The Safety and Efficacy of DCA for the Treatment of Brain Cancer

Malignant Gliomas, Glioblastoma Multiforme

Canada
National Cancer Institute (NCI)

Active, not recruiting

Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)

Malignant Glioma | Recurrent Childhood Ependymoma | Rhabdoid Tumor | Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Recurrent Hepatoblastoma | Recurrent Langerhans Cell Histiocytosis | Recurrent Malignant Solid Neoplasm | Recurrent Medulloblastoma | Recurrent Neuroblastoma | Recurrent... and other conditions

United States, Puerto Rico
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

AOH1996 for the Treatment of Refractory Solid Tumors

Refractory Malignant Solid Neoplasm

United States
University of Southern California
National Cancer Institute (NCI)

Recruiting

FID-007 in Treating Participants With Advanced Solid Tumors

Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm

United States
National Cancer Institute (NCI)

Completed

AZD1775 in Treating Patients With Advanced Refractory Solid Tumors With CCNE1 Amplification

Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm

United States
National Cancer Institute (NCI)

Suspended

Testing the Use of Nilotinib and Paclitaxel as a Treatment for Patients With Prior Taxane Treatment, A ComboMATCH Treatment Trial

Refractory Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm

United States
National Cancer Institute (NCI)

Active, not recruiting

Trametinib and Navitoclax in Treating Patients With Advanced or Metastatic Solid Tumors

Refractory Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm

United States
Children's Oncology Group
National Cancer Institute (NCI); Incuron LLC

Recruiting

CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma

Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Recurrent Lymphoma | Recurrent Malignant Solid Neoplasm | Recurrent Osteosarcoma | Refractory Osteosarcoma | Diffuse Midline Glioma, H3 K27M-Mutant | Recurrent Diffuse Intrinsic Pontine Glioma | Metastatic Malignant Neoplasm in the Central... and other conditions

United States
M.D. Anderson Cancer Center

Active, not recruiting

Avelumab and M6620 for the Treatment of DDR Deficient Metastatic or Unresectable Solid Tumors

Refractory Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm

United States
M.D. Anderson Cancer Center

Recruiting

Cabozantinib and Pamiparib for the Treatment of Advanced of Refractory Solid Tumors

Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm

United States
Ruijin Hospital
UTC Therapeutics Inc.

Recruiting

Anti-mesothelin CAR-T Cells With Advanced Refractory Solid Tumors (Amaretto)

Refractory Malignant Solid Neoplasm

China
National Cancer Institute (NCI)
Children's Oncology Group

Recruiting

Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)

Malignant Solid Neoplasm | Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Recurrent Ependymoma | Recurrent Hepatoblastoma | Recurrent Langerhans Cell Histiocytosis | Recurrent Malignant Germ Cell Tumor | Recurrent Malignant Glioma | Recurrent Malignant Solid Neoplasm | Recurrent... and other conditions

United States, Puerto Rico, Australia
Gustave Roussy, Cancer Campus, Grand Paris

Completed

Temozolomide in Association With Topotecan in Refractory or Relapsed Malignant Tumors in Children and Adolescents

Malignant Tumors | Refractory Tumors

France
National Cancer Institute (NCI)

Active, not recruiting

Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial

Malignant Solid Neoplasm | Recurrent Melanoma | Recurrent Ependymoma | Recurrent Ewing Sarcoma | Recurrent Hepatoblastoma | Recurrent Langerhans Cell Histiocytosis | Recurrent Malignant Germ Cell Tumor | Recurrent Malignant Glioma | Recurrent Medulloblastoma | Recurrent Neuroblastoma | Recurrent Non-Hodgkin... and other conditions

United States, Puerto Rico
Tactical Therapeutics, Inc.

Active, not recruiting

Safety and Tolerability of Carboxyamidotriazole Orotate (CTO) in Solid Tumors or With Temodar® in Glioblastoma or Other Recurrent Malignant Gliomas or in Combination With Temodar® and Radiation Therapy for Patients With Newly Diagnosed Glioblastoma and Malignant Gliomas

Solid Tumors, Glioblastoma, Recurrent Malignant Gliomas

United States
National Cancer Institute (NCI)

Recruiting

Testing the Combination of Anti-cancer Drugs Atezolizumab and Tiragolumab in People With Advanced Stage Rare Cancers, RARE3 Trial

Advanced Rare Malignant Solid Neoplasm | Rare Malignant Solid Neoplasm | Refractory Rare Malignant Solid Neoplasm

United States
National Cancer Institute (NCI)

Active, not recruiting

Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)

Recurrent Childhood Medulloblastoma | Recurrent Childhood Ependymoma | Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Recurrent Hepatoblastoma | Recurrent Langerhans Cell Histiocytosis | Recurrent Malignant Glioma | Recurrent Malignant Solid Neoplasm | Recurrent Neuroblastoma and other conditions

United States, Puerto Rico
National Cancer Institute (NCI)

Active, not recruiting

Testing the Sequential Combination of the Anti-cancer Drugs Olaparib Followed by Adavosertib (AZD1775) in Patients With Advanced Solid Tumors With Selected Mutations and PARP Resistance, STAR Study

Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm

United States
Children's Oncology Group
National Cancer Institute (NCI)

Active, not recruiting

Selinexor in Treating Younger Patients With Recurrent or Refractory Solid Tumors or High-Grade Gliomas

Malignant Glioma | WHO Grade 3 Glioma | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Recurrent Lymphoma | Recurrent Malignant Solid Neoplasm | Refractory Primary Central Nervous System Neoplasm | Recurrent Childhood Central Nervous System Neoplasm | Recurrent Brain Neoplasm | Recurrent Childhood...

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors

Refractory Malignant Solid Neoplasm | Recurrent Malignant Solid Neoplasm | Recurrent Cutaneous Melanoma | Recurrent Malignant Female Reproductive System Neoplasm | Refractory Malignant Female Reproductive System Neoplasm | Recurrent Lip and Oral Cavity Carcinoma | Recurrent Malignant Endocrine... and other conditions

United States
National Cancer Institute (NCI)
Children's Oncology Group

Active, not recruiting

Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)

Recurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Rhabdoid Tumor | Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Ann Arbor Stage III Hodgkin Lymphoma | Ann Arbor Stage IV Hodgkin Lymphoma | Recurrent Ependymoma | Recurrent Ewing Sarcoma | Recurrent Hepatoblastoma | Recurrent... and other conditions

United States, Puerto Rico
National Cancer Institute (NCI)

Active, not recruiting

Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)

Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Recurrent Ewing Sarcoma | Recurrent Hepatoblastoma | Recurrent Histiocytic and Dendritic Cell Neoplasm | Recurrent Langerhans Cell Histiocytosis | Recurrent Malignant Germ Cell Tumor | Recurrent Malignant Solid Neoplasm | Recurrent... and other conditions

United States, Puerto Rico
Gustave Roussy, Cancer Campus, Grand Paris

Completed

Study Of Vinblastine in Combination With Nilotinib in Children, Adolescents and Young Adults (VINILO)

Refractory Low-grade Gliomas | Recurrent Low-grade Gliomas

Austria, Italy, France, Denmark, Netherlands, Spain, Switzerland, United Kingdom
Gustave Roussy, Cancer Campus, Grand Paris
Innovative Therapies For Children with Cancer Consortium

Terminated

Study of Vinblastine in Combination With Nilotinib in Children, Adolescents, and Young Adults (VINILO)

Refractory Low-grade Gliomas | Recurrent Low-grade Gliomas

Austria, Italy, France, Denmark, Netherlands, Spain, Switzerland, United Kingdom
National Cancer Institute (NCI)

Suspended

Testing Olaparib and AZD6738 in IDH1 and IDH2 Mutant Tumors

Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Refractory Cholangiocarcinoma

United States
National Cancer Institute (NCI)

Completed

ZD6474 to Treat Advanced Brain Cancer in Patients

Recurrent High-Grade Gliomas | Malignant Gliomas | Progressive Low-Grade Gliomas

United States
Memorial Sloan Kettering Cancer Center
Columbia University; Genentech, Inc.; University of California, San Francisco

Completed

Hypofractionated Stereotactic Radiotherapy With Bevacizumab in the Treatment of Recurrent Malignant Glioma

Glioblastoma | Brain Cancer | Anaplastic Astrocytoma (AA) | Anaplastic Oligodendroglioma (AO) | MALIGNANT GLIOMA | Anaplastic Oligo-astrocytoma (AOA) | Anaplastic Mixed Gliomas | Malignant Glioma NOS

United States

Clinical Trials on Refractory Malignant Glioma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Malaysia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations